Dr Verschraegen Inge, klinisch bioloog
0841.325.243 · rovalta.com · 26/09/2026
Dr Verschraegen Inge, klinisch bioloog
Financial year 2025 · Closed on 30/06/2025
Overview
Identity
Source · BCE/KBODr Verschraegen Inge, klinisch bioloog is a Private limited company incorporated in 2011. Its main activity is: Specialist medical practice activities. Its registered office is in Laarne.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0841.325.243
- Incorporation
- 25/11/2011
- Legal form
- Private limited company
- Registered office
- Boombosstraat 51
9270 Laarne · FlandreSee on map - Contributed capital
- 12 400,00 €
- Latest accounts
- 30/06/2025
Financials
Source · NBB, 13 filingsTrend over 13 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 207,9 k € | +25.4% | 165,9 k € | -2.2% | 169,7 k € | -48.4% | 329,1 k € | +211% | 106 k € |
| EBITDA | 203,8 k € | +26.6% | 161 k € | -3.7% | 167,2 k € | -48.8% | 326,3 k € | +216% | 103,2 k € |
| Operating result | 166,1 k € | +20.6% | 137,7 k € | -2.2% | 140,9 k € | -47.7% | 269,3 k € | +469% | 47,3 k € |
| Net result | 103,5 k € | +18.5% | 87,3 k € | +0.4% | 87 k € | -50.1% | 174,2 k € | +730% | 21 k € |
| Balance sheet | |||||||||
| Equity | 524,2 k € | +19.2% | 439,7 k € | +24.5% | 353,2 k € | +23.0% | 287,2 k € | +91.1% | 150,3 k € |
| Total assets | 771,8 k € | +7.7% | 716,8 k € | +26.3% | 567,5 k € | +2.7% | 552,4 k € | +21.5% | 454,8 k € |
| Cash | 118,2 k € | -0.4% | 118,7 k € | +88.3% | 63 k € | -67.8% | 196,1 k € | +1188% | 15,2 k € |
| Debts | 247,4 k € | -10.7% | 276,9 k € | +29.3% | 214,1 k € | -19.2% | 264,9 k € | -3.9% | 275,7 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 30/06/20251 active · 2 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/07/2024 | 01/07/2023 | 01/07/2022 | 01/07/2021 | 01/07/2020 | 01/07/2019 |
| Closing of the financial year | 30/06/2025 | 30/06/2024 | 30/06/2023 | 30/06/2022 | 30/06/2021 | 30/06/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 17/01/2026 | 31/01/2025 | 30/01/2024 | 21/12/2022 | 31/01/2022 | 23/12/2020 |
| General meeting | 18/12/2025 | 19/12/2024 | 15/11/2023 | 15/11/2022 | 15/11/2021 | 15/11/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 13 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 30/06/2025 | 18/12/2025 | 17/01/2026 | Dutch | |
| Micro model | 30/06/2024 | 19/12/2024 | 31/01/2025 | Dutch | |
| Micro model | 30/06/2023 | 15/11/2023 | 30/01/2024 | Dutch | |
| Micro model | 30/06/2022 | 15/11/2022 | 21/12/2022 | Dutch | |
| Micro model | 30/06/2021 | 15/11/2021 | 31/01/2022 | Dutch | |
| Micro model | 30/06/2020 | 15/11/2020 | 23/12/2020 | Dutch | |
| Micro model | 30/06/2019 | 15/11/2019 | 03/02/2020 | Dutch | |
| Abridged model | 30/06/2018 | 30/11/2018 | 20/12/2018 | Dutch | |
| Abridged model | 30/06/2017 | 30/11/2017 | 21/12/2017 | Dutch | |
| Abridged model | 30/06/2016 | 30/11/2016 | 28/12/2016 | Dutch | |
| Abridged model | 30/06/2015 | 15/11/2015 | 24/11/2015 | Dutch | |
| Abridged model | 30/06/2014 | 15/11/2014 | 15/01/2015 | Dutch | |
| Abridged model | 30/06/2013 | 15/11/2013 | 09/01/2014 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 30/06/20251 active · 2 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official GazetteSimilar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025103,5 k €↑
- 2024Annual accounts 202487,3 k €↑
- 2024Name changeDr. Verschraegen Inge, Klinisch bioloog
- 2023Annual accounts 202387 k €↓
- 2022Annual accounts 2022174,2 k €↑
- 2022Name changeDr. Verschraegen Inge
- 2021Annual accounts 202121 k €↓
- 2020Annual accounts 202039,3 k €↑
- 2019Annual accounts 201918,1 k €↓
- 2018Annual accounts 201841 k €↑
- 2017Annual accounts 201726,3 k €↓
- 2016Annual accounts 201636 k €↑
- 2015Annual accounts 201527,9 k €↓
- 2014Annual accounts 201431,8 k €↓
- 2013Annual accounts 201361,1 k €
- 25/11/2011IncorporationPrivate limited company